TCA
FOLD

Transcend Capital Advisors’s Amicus Therapeutics FOLD Stock Holding History

Transcend Capital Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-364,383
Closed -$2.97M – 646
2025
Q1 		$2.97M Buy
364,383
+470
+0.1% +$4.35K 0.21% 116
2024
Q4 		$3.43M Buy
363,913
+37,059
+11% +$385K 0.25% 101
2024
Q3 		$3.49M Sell
326,854
-3,473
-1% -$37.8K 0.23% 110
2024
Q2 		$3.28M Buy
330,327
+20,005
+6% +$205K 0.24% 105
2024
Q1 		$3.66M Buy
310,322
+344
+0.1% +$4.4K 0.29% 84
2023
Q4 		$4.4M Buy
309,978
+23,474
+8% +$267K 0.39% 56
2023
Q3 		$3.48M Buy
286,504
+359
+0.1% +$4.63K 0.34% 65
2023
Q2 		$3.59M Buy
286,145
+69,686
+32% +$827K 0.34% 67
2023
Q1 		$2.4M Buy
216,459
+773
+0.4% +$9.53K 0.25% 104
2022
Q4 		$2.63M Buy
215,686
+617
+0.3% +$6.95K 0.29% 87
2022
Q3 		$2.25M Buy
215,069
+18,873
+10% +$210K 0.25% 107
2022
Q2 		$2.11M Buy
196,196
+52,975
+37% +$436K 0.22% 122
2022
Q1 		$1.36M Buy
143,221
+1,157
+0.8% +$10.8K 0.12% 181
2021
Q4 		$1.64M Sell
142,064
-800
-0.6% -$8.92K 0.14% 162
2021
Q3 		$1.48M Buy
142,864
+1,800
+1% +$18.4K 0.13% 169
2021
Q2 		$1.36M Sell
141,064
-4,000
-3% -$39K 0.2% 127
2021
Q1 		$1.43M Buy
145,064
+35,209
+32% +$545K 0.17% 137
2020
Q4 		$2.54M Buy
+109,855
New +$2.25M 0.33% 79

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Transcend Capital Advisors's FOLD Position: Q2 2025 in Review

Transcend Capital Advisors sold out of Amicus Therapeutics (FOLD) in Q2 2025, closing a stake of 364,383 shares — an estimated $2.97M sold.

Transcend Capital Advisors first reported a position in FOLD in Q4 2020 and held it in 18 quarters. The position peaked at $4.4M in Q4 2023. 272 funds tracked by Wall St. Rank hold FOLD as of Q2 2025.

  • Transcend Capital Advisors reported no remaining Amicus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Transcend Capital Advisors sold 364,383 Amicus Therapeutics shares in Q2 2025, an estimated $2.97M.
  • Transcend Capital Advisors first reported a position in Amicus Therapeutics in Q4 2020 and held it in 18 quarters.
  • Transcend Capital Advisors's Amicus Therapeutics position peaked at $4.4M in Q4 2023.
  • 272 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2025.

Based on Transcend Capital Advisors's 13F filing for Q2 2025, filed 1 Aug 2025.